Portfolio Risk
Cash runway vs days to next catalyst — spot binary event risk at a glance
| Company | Catalyst | Type | Days | Runway | Impact | Confidence |
|---|---|---|---|---|---|---|
| TLX | TLX101-Px (Pixclara) FDA PDUFA Decision | Regulatory | 2d | CF+ | high | confirmed |
| CU6 | AMPLIFY Phase 3 topline data | Data Readout | 21d | 27mo | high | expected |
| CSL | Garadacimab FDA filing decision | Regulatory | 21d | CF+ | high | expected |
| MSB | CHF Phase 3 interim data | Data Readout | 21d | 24mo | high | expected |
| SPL | DEP cabazitaxel Phase 2 update | Data Readout | 21d | 10mo | medium | expected |
| IMM | IMP761 Phase I MAD completion | Data Readout | 21d | CF+ | high | expected |
| AVH | PermeaDerm I study data readout | Data Readout | 21d | CF+ | medium | expected |
| AVR | Medtronic co-commercialization agreement details | partnership | 21d | 1mo | high | expected |
| 1AD | BZDS1901 first manufacturing runs in Australia | Commercial | 21d | 1mo | high | expected |
| 1AD | BZDS1901 FDA pre-IND meeting | Regulatory | 21d | 1mo | high | expected |
| SNT | SNT-4728 Phase 2 iRBD full results including digital and biological markers | Data Readout | 21d | 25mo | high | expected |
| COH | Nucleus Nexa System global rollout | Commercial | 21d | CF+ | medium | expected |
| PME | First digital pathology client deployment | Commercial | 21d | CF+ | high | expected |
| ILA | ISLA-101 end of Phase 2 meeting with FDA | Regulatory | 21d | 32mo | high | expected |
| IIQ | US CLIA laboratory partner announcement | partnership | 21d | 11mo | high | speculative |
| PAB | RLS-2202 Phase 1A first participant dosing | Regulatory | 21d | 13mo | high | expected |
| PAR | PARA_OA_012 Phase 3 Interim Analysis Results | Data Readout | 21d | 3mo | high | expected |
| NYR | PROTECT-MI recruitment acceleration | Commercial | 21d | CF+ | medium | expected |
| CSL | PHASE2 data readout — Zemaira Eosinophilic Esophagitis Pilot Study | Data Readout | 22d | CF+ | medium | speculative |
| ACW | PHASE2/PHASE3 data readout — Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease | Data Readout | 22d | 3mo | medium | speculative |
| RMD | Trial data readout — Exploration of Current and New Technologies for Accuracy of Diagnosing OSA | Data Readout | 22d | CF+ | medium | speculative |
| FPH | Trial data readout — Evaluation of the Effects on Carbon Dioxide (paCO2) of a New Oronasal Mask in Pa | Data Readout | 22d | CF+ | medium | speculative |
| GTG | Trading resumption plan deadline | Regulatory | 42d | 0mo | high | confirmed |
| AVR | TCT 2026 DurAVR clinical data presentation | Conference | 52d | 1mo | medium | confirmed |
| TLX | ProstACT Global Phase 2 Part 2 U.S. Enrollment Initiation | Commercial | 52d | CF+ | high | expected |
| RAD | RAD101 Phase 3 Pivotal Trial Initiation | Commercial | 52d | 4mo | high | expected |
| BDX | R&D tax offset receipt | Financing | 52d | 3mo | medium | expected |
| TLX | PHASE1 data readout — PSMA PET Response Guided SabR in High Risk Pca | Data Readout | 53d | CF+ | medium | speculative |
| KZA | PHASE1 data readout — GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain | Data Readout | 83d | 0mo | medium | speculative |
| IMR | Trial data readout — VT Ablation in the iCMR | Data Readout | 83d | CF+ | medium | speculative |